- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01748734
Cognitive Therapy in Reducing Depression in Patients With Cancer
An Examination of Cognitive Therapy for Depression in Cancer Patients.
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the efficacy of biobehavioral/cognitive therapy for cancer patients/survivors with major depression.
II. Test for the covariation between reduction in depressive symptoms and improvements in quality of life.
OUTLINE:
Patients undergo cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
After completion of study treatment, patients are followed up at 3, 6, and 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prior diagnosis of invasive cancer, any site, any stage, any time since diagnosis; history of non malignant (basal cell) or low malignant potential (e.g., in situ cervix) cancers do not meet this criterion
- Diagnosis of major depressive disorder (MDD), according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria (American Psychiatric Association, 2000)
- Able and willing to give informed consent
Exclusion Criteria:
- History of bipolar affective disorder or psychosis
- Current axis I disorder (e.g. obsessive-compulsive disorder, specific phobia) other than MDD if it constitutes the predominant aspect of the clinical presentation and if it requires treatment other than that being offered
- History of substance dependence in the past six months
- Subnormal intellectual potential (intelligence quotient [IQ] below 80)
- Current suicide risk sufficient to preclude treatment on an outpatient basis
- Progressive neurological or related conditions/diagnoses
- Non-ambulatory
- Life expectancy less than 60 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Supportive care (cognitive behavioral therapy)
Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
|
Ancillary studies
Ancillary studies
Other Names:
Undergo cognitive behavioral therapy
Other Names:
Undergo cognitive behavioral therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psychiatric diagnoses, using the Structured Clinical Interview for the DSM-IV (SCID)
Time Frame: Up to 12 months
|
Only modules for mood disorders, anxiety disorders, and substance use disorders will be used.
The Global Assessment of Functioning (GAF) Scale will be included as part of the SCID interview.
The Longitudinal Interview Follow-Up Evaluation (LIFE) will be used to assess psychosocial, diagnostic, and treatment information.
Alpha level will be set at 0.05, beta at 0.20.
95% confidence intervals will be obtained for all outcome measures.
|
Up to 12 months
|
Hamilton Rating Scale for Depression (HRSC) as a measure of depressive symptom severity
Time Frame: Up to 12 months
|
The modified 17-item HRSD interview codes both responses and behavior.
Complete remission of depressive symptoms is indicated by scores of 7 or less, partial remission by scores 8-12, and no remission by scores of 13 or greater.
Alpha level will be set at 0.05, beta at 0.20.
95% confidence intervals will be obtained for all outcome measures.
|
Up to 12 months
|
Beck Depression Inventory - 2nd Edition (BDI-II) used to assess the severity of symptoms of depression
Time Frame: Up to 12 months
|
The BDI-II is a 21-item self-report instrument.
Respondents describe their feelings during the past week by rating each item on a scale from 0-3.
Thus, possible scores are 0 (minimal depression) to 63 (high depression).
Complete remission is indicated by scores of 9 or less, partial remission by scores of 10-16, and no remission by scores of 17 or greater.
Alpha level will be set at 0.05, beta at 0.20.
95% confidence intervals will be obtained for all outcome measures.
|
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stress, as measured by the life events scale and the cancer-related Impact of Events Scale (IES)
Time Frame: Up to 12 months
|
Life events scale, patients indicate experience of any of 5 stressful life events during the previous year and rate how emotionally upsetting the event was.
Scores calculated for presence of each event (0-1), total number of events (0-5), and sum of the distress ratings (0-15).
The IES is a 22-item self report questionnaire to assess reactions to cancer diagnosis and treatment.
It measures frequency of intrusive thoughts, avoidant thoughts/behaviors, and hyperarousal during the previous week using a 4-point Likert scale.
Items summed for total scores ranging from 0-75.
|
Up to 12 months
|
Distress, as measured by the Profile of Mood States (POMS), Center for Epidemiological Studies Depression Scale (CES-D) Iowa short form, and the Beck Hopelessness Scale (HS)
Time Frame: Up to 12 months
|
POMS is a 65-item self report inventory yielding a total mood disturbance scale and 6 mood subscales on a 5-point Likert scale.
Total score is sum of subscale scores and ranges from -32 to 200.
CES-D is an 11-item form rated on a 3-point Likert scale.
All items are summed with total scores ranging from 0 to 22. HS is a 20-item true-false form with scores ranging from 0 to 20.
Alpha level will be set at 0.05, beta at 0.20.
95% confidence intervals will be obtained for all outcome measures.
|
Up to 12 months
|
Quality of life, as measured by Medical Outcomes Study Short Form, Meaning in Life Scale (MiL), Satisfaction with Life Scale (SWLS), Fatigue Symptom Inventory-Revised (FSI), Brief Pain Questionnaire (BPQ), and Charlson Comorbidity Index (CCI)
Time Frame: Up to 12 months
|
Medical Outcomes Study Short Form is 36-item scale with 8 subscales with scores ranging 0-100.
MiL is 21-item scale with 4 dimensions; subscale scores range from 1 to 6 and summary scores range from 3 to 17. SWLS is a 5-item scale measured on a 7-point scale for total scores ranging from 5 to 35.
FSI is a 14-item measure with scores ranging from 0 to 70.
BPI has scales with ratings from 0 to 10. CCI has total scores ranging from 0 to 37 (age unadjusted) or 0 to 43 (age adjusted).
Alpha level will be set at 0.05, beta at 0.20.
95% confidence intervals will be obtained for all outcome measures.
|
Up to 12 months
|
Social relationships, as measured by a single item from the Dyadic Adjustment Scale (DAS), a short form of the Sexual Experience Scale, and the Perceived Social Support From Friends (PSS-Fr) and Family (PSS-Fa)
Time Frame: Up to 12 months
|
DAS subscale for Affectional Expression used, rates overall relationship happiness from 0-6.
Short form of the Sexual Experience Scale includes 3 items rated on a 9-point frequency scale.
PSS-Fr and PSS-Fa are two 20-item instruments with total scores ranging from 0 to 20 for both scales.
Alpha level will be set at 0.05, beta at 0.20.
95% confidence intervals will be obtained for all outcome measures.
|
Up to 12 months
|
Therapy process & therapy mediators measured by Working Alliance Inventory (WAI), Expectations for Therapy, Attributional Style, COPE, Implicit Self-Relevant Beliefs Assessment (ISRBA), Ways of Responding (WOR), & Evaluation of Topics of the Intervention
Time Frame: Up to 12 months
|
WAI short assesses trust, confidence, and understanding and commitment to completing homework.
Expectations for Therapy assesses expectations with regards to efficacy, type, and response.
Attributional Style measures optimism.
Brief COPE is a 28-item scale with 14 subscales; score ranges are 0 to 6. ISRBA is a computer-based assessment measuring valence of implicit self-relevant beliefs.
WOR scale measures compensatory skills thought to be acquired in cognitive therapy for depression.
Evaluation of Topics of the Intervention is an 11-item scale rating each component on a 4-point Likert scale.
|
Up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Barbara Andersen, Ph.D., Ohio State University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-07043
- NCI-2012-00738 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on questionnaire administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation